Skip to main content

Our unique collection of technologies/capabilities places us at the forefront of HFpEF research. Using these strategies, our aims are as follows:

  1. Determine key mechanistic underpinnings in each subclass of HFpEF.
  2. Develop novel management strategies and treatment guidelines to treat each HFpEF subclass (with Dr Sean Lal, co-Director of HFpEF clinic and Director of Sydney Heart Bank).
  3. Develop novel therapeutics to improve HFpEF outcome (with Dr Xuyu Liu, HRI).

Outcomes: New management guidelines and therapeutic agents for HFpEF, the most common form of heart failure globally that currently has no approved pharmacotherapies.

Questions about mRNA vaccines and heart...

Get the answers